How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story
Recently, Taysha Gene Therapies announced it has regained full rights to its lead gene therapy candidate TSHA-102 for…
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
BiomX Inc Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot…